These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21913738)

  • 21. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A; Marai I; Appel S; Zimlichman E
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy.
    Ahsan N
    J Nephrol; 1998; 11(3):157-61. PubMed ID: 9650125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation.
    Chapman SA; Gilkerson KL; Davin TD; Pritzker MR
    Ann Pharmacother; 2004 Dec; 38(12):2059-67. PubMed ID: 15536143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: thrombotic microangiopathy post-intravenous immunoglobulin in the context of BK nephropathy and renal transplantation.
    Pan FF; Hidayati L; Hughes P; Murugasu A; Masterson R
    Transplant Proc; 2014; 46(1):278-80. PubMed ID: 24507067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy.
    Lee YJ; Shin JU; Lee J; Kim K; Kim WS; Ahn JS; Jung CW; Kang WK
    J Korean Med Sci; 2007 Aug; 22(4):758-61. PubMed ID: 17728525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
    Lidar M; Masarwa S; Rotman P; Carmi O; Rabinowicz N; Levy Y
    Immunol Res; 2018 Dec; 66(6):668-674. PubMed ID: 30565202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombotic complications after intravenous immunoglobulin therapy in two patients.
    Emerson GG; Herndon CN; Sreih AG
    Pharmacotherapy; 2002 Dec; 22(12):1638-41. PubMed ID: 12495174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin and the kidney--a two-edged sword.
    Orbach H; Tishler M; Shoenfeld Y
    Semin Arthritis Rheum; 2004 Dec; 34(3):593-601. PubMed ID: 15609263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study.
    Melamed IR; Miranda H; Heffron M; Harper JR
    Front Immunol; 2021; 12():632744. PubMed ID: 33737935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
    Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
    Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
    Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
    Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of high infusion rate IVIG in CIDP.
    Jiang Y; Mendoza M; Sarpong E; Mannan S; Ng E; Katzberg H; Bril V; Barnett C
    Muscle Nerve; 2020 Nov; 62(5):637-641. PubMed ID: 32785949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.
    Huang L; Kanellis J; Mulley W
    Nephrology (Carlton); 2011 Feb; 16(2):239-42. PubMed ID: 21272138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital.
    Güngör A; Yarali N
    Saudi Med J; 2020 Feb; 41(2):163-167. PubMed ID: 32020150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients.
    Bollée G; Anglicheau D; Loupy A; Zuber J; Patey N; Mac Gregor D; Martinez F; Mamzer-Bruneel MF; Snanoudj R; Thervet E; Legendre C; Noël LH
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1461-8. PubMed ID: 18525007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute kidney injury due to sucrose-containing intravenous immunoglobulins.
    Siddiqui W; Al Lawati S; Shaheen Faissal AM; Hannawi S; Al Riyami M; Al Salmi I
    Saudi J Kidney Dis Transpl; 2019; 30(3):732-737. PubMed ID: 31249243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature].
    Decocq G; de Cagny B; Andréjak M; Desablens B
    Therapie; 1996; 51(5):516-26. PubMed ID: 9138386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.